Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Valente

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Medchemcomm|August 16, 2018
Triazolopyrimidines identified as reversible myeloperoxidase inhibitorsFranck Duclos, Lynn M Abell, David G Harden, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery of Highly Potent Liver X Receptor β AgonistsEllen K Kick, Brett B Busch, Richard Martin, et al.
Journal of Medicinal Chemistry|February 17, 2026
From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective <i>N</i>-Formyl Peptide Receptor 2 AgonistPravin S Shirude, Daniel Cheney, Amit K Chattopadhyay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)A Younes, P Hilden, B Coiffier, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Medchemcomm|August 16, 2018
Triazolopyrimidines identified as reversible myeloperoxidase inhibitorsFranck Duclos, Lynn M Abell, David G Harden, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery of Highly Potent Liver X Receptor β AgonistsEllen K Kick, Brett B Busch, Richard Martin, et al.
Journal of Medicinal Chemistry|February 17, 2026
From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective <i>N</i>-Formyl Peptide Receptor 2 AgonistPravin S Shirude, Daniel Cheney, Amit K Chattopadhyay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)A Younes, P Hilden, B Coiffier, et al.
Pageof 4